Editorial Feature

Using Quantum Dots to Treat Parkinson’s and Alzheimer’s Disease

Image Credits: PopTika/shutterstock.com

There is currently no cure for Alzheimer’s or Parkinson’s disease. There are medications to treat the symptoms of both conditions, and a great deal of research is being done into new and more effective treatments, including those drawing on quantum physics.

What are Parkinson’s and Alzheimer’s Disease?

Parkinson’s disease is a progressive neurological condition that causes extensive damage to brain cells resulting in involuntary shaking and tremors, slow movement, and stiff muscles. There are also associated memory problems, balance problems, and anosmia and insomnia, as well as psychological conditions including depression and anxiety.

Alzheimer’s disease is the most common cause of dementia. The exact cause of Alzheimer’s disease is not yet fully understood but there are a number of risk factors that contribute to a person’s chances of developing the neurological condition. These include increased age and lifestyle factors associated with cardiovascular disease and a family history of the condition.

Treatment for Parkinson’s and Alzheimer’s with Quantum Dots

Research into using quantum dots to treat Alzheimer’s and Parkinson’s is an emerging science. A paper published in Nature Nanotechnology in 2018 reported that graphene quantum dots (GQDs) were able to inhibit fibrillization of α-synuclein and prevent their aggregation.

GQDs represent layers of graphene sized less than 30 nm, from one single layer of graphene to tens of layers. Studies have shown that GQDs, in particular, are not just single layers but multi-layered formations made up of 10 layers of reduced graphene oxide from a size of 10 to 60 nm.

Α-synuclein (a protein found in large amounts in the human brain) accumulation has been attributed to the development of Parkinson’s disease.

Also found in the heart, muscles, and gut, α-synuclein is found near the ends of the neurons that are used to release chemicals between neurons.

The exact function of α-synuclein is not fully understood, but it has been associated with the regulation of the release of dopamine. Dopamine is a critical element in Parkinson’s disease as it controls voluntary and involuntary movements.

In Parkinson’s, α-synuclein misfolds and forms aggregates (called Lewy bodies), which, as they grow in size, contribute to brain cell death. It is not understood what triggers this process but it is perhaps problems in the process of protein regulation and recycling that leads to aggregation. As such, being able to halt the accumulation of α-synuclein is thought to improve disease outcome in Parkinson’s.

GQDs have been found to limit neuronal death and synaptic loss, reduce Lewy bodies and the formation of Lewy neurites, improve mitochondrial dysfunction and prevent α-synuclein from transmitting between neurons. After penetrating the blood-brain barrier (that they can achieve due to their miniature size, unlike most medicine), GQDs are also able to protect against dopamine neuron loss.

The study found that quantum dots made from graphene bound to α-synuclein and stopped it from accumulating, and also caused any existing toxic clumps to break down into individual molecules.

This particular study was carried out on mice and has yet to be tested in humans. As such, the specific effects on humans are difficult to quantify, as human bodies are far more complex and past innovations for the treatment of both Alzheimer’s and Parkinson’s have not always produced the same benefits in humans as they have in mouse models. However, in these mice tests conducted in 2018, Parkinson’s symptoms were shown to significantly improve.

A separate study has also found promise in quantum dot treatments for Alzheimer’s disease, which works by a similar mechanism to the GQD treatment for Parkinson’s. The quantum dots bind to a protein called amyloid, and as is seen in Parkinson’s, prevent the protein from aggregating.

Future Focuses

In the future, drugs based on graphene quantum dots may provide valuable information for the development of new therapeutic drugs or abnormal protein aggregation-related neurological conditions such as Parkinson’s disease, but more research needs to be done to determine whether benefits seen in mice studies will translate to humans.

Sources and Further Reading

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Lois Zoppi

Written by

Lois Zoppi

Lois is a freelance copywriter based in the UK. She graduated from the University of Sussex with a BA in Media Practice, having specialized in screenwriting. She maintains a focus on anxiety disorders and depression and aims to explore other areas of mental health including dissociative disorders such as maladaptive daydreaming.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Zoppi, Lois. (2019, August 26). Using Quantum Dots to Treat Parkinson’s and Alzheimer’s Disease. AZoQuantum. Retrieved on May 23, 2024 from https://www.azoquantum.com/Article.aspx?ArticleID=125.

  • MLA

    Zoppi, Lois. "Using Quantum Dots to Treat Parkinson’s and Alzheimer’s Disease". AZoQuantum. 23 May 2024. <https://www.azoquantum.com/Article.aspx?ArticleID=125>.

  • Chicago

    Zoppi, Lois. "Using Quantum Dots to Treat Parkinson’s and Alzheimer’s Disease". AZoQuantum. https://www.azoquantum.com/Article.aspx?ArticleID=125. (accessed May 23, 2024).

  • Harvard

    Zoppi, Lois. 2019. Using Quantum Dots to Treat Parkinson’s and Alzheimer’s Disease. AZoQuantum, viewed 23 May 2024, https://www.azoquantum.com/Article.aspx?ArticleID=125.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this article?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.